Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2017

01-10-2017 | Review

The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials

Authors: Kedar R. Mahajan, Daniel Ontaneda

Published in: Neurotherapeutics | Issue 4/2017

Login to get access

Abstract

Magnetic resonance imaging has been crucial in the development of anti-inflammatory disease-modifying treatments. The current landscape of multiple sclerosis clinical trials is currently expanding to include testing not only of anti-inflammatory agents, but also neuroprotective, remyelinating, neuromodulating, and restorative therapies. This is especially true of therapies targeting progressive forms of the disease where neurodegeneration is a prominent feature. Imaging techniques of the brain and spinal cord have rapidly evolved in the last decade to permit in vivo characterization of tissue microstructural changes, connectivity, metabolic changes, neuronal loss, glial activity, and demyelination. Advanced magnetic resonance imaging techniques hold significant promise for accelerating the development of different treatment modalities targeting a variety of pathways in MS.
Appendix
Available only for authorised users
Literature
1.
Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol 2013;12(7):669-676.CrossRefPubMed
2.
3.
van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50(5):1282-1288.CrossRefPubMed
4.
Tam RC, Traboulsee A, Riddehough A, Sheikhzadeh F, Li DK. The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis. Mult Scler 2011;17(8):949-957.CrossRefPubMed
5.
Gabr RE, Hasan KM, Haque ME, Nelson FM, Wolinsky JS, Narayana PA. Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis. J Magn Reson Imaging 2016;44(5):1293-1300.PubMedCentralCrossRefPubMed
6.
Obusez EC, Lowe M, Oh SH, et al. 7T MR of intracranial pathology: Preliminary observations and comparisons to 3T and 1.5T. NeuroImage 2016 Nov 30.
7.
Saake M, Langner S, Schwenke C, et al. MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. Eur Radiol 2016;26(3):820-828.CrossRefPubMed
8.
Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007;62(3):219-228.CrossRefPubMed
9.
Vollmer T, Signorovitch J, Huynh L, et al. The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis. J Neurol Sci 2015;357(1-2):8-18.CrossRefPubMed
10.
Zivadinov R, Uher T, Hagemeier J, et al. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 2016;22(13):1709-1718.CrossRefPubMed
11.
Aubert-Broche B, Fonov V, Narayanan S, et al. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology 2014;83(23):2140-2146.PubMedCentralCrossRefPubMed
12.
Jacobsen C, Hagemeier J, Myhr KM, et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014;85(10):1109-1115.CrossRefPubMed
13.
Mellergard J, Tisell A, Blystad I, et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol 2017;24(1):112-121.CrossRefPubMed
14.
Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383(9936):2213-2221.CrossRefPubMed
15.
Barkhof F, Scheltens P, Frequin ST, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159(5):1041-1047.CrossRefPubMed
16.
Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25(1):43-49.CrossRefPubMed
17.
Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64(10):1416-1422.CrossRefPubMed
18.
Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11(12):1082-1092.CrossRefPubMed
19.
Roosendaal SD, Moraal B, Vrenken H, et al. In vivo MR imaging of hippocampal lesions in multiple sclerosis. J Magn Reson Imaging 2008;27(4):726-731.CrossRefPubMed
20.
Louapre C, Govindarajan ST, Gianni C, et al. The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI. NeuroImage Clin 2016;12:879-886.PubMedCentralCrossRefPubMed
21.
Kilsdonk ID, Jonkman LE, Klaver R, et al. Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain 2016;139(Pt 5):1472-1481.CrossRefPubMed
22.
Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012;78(5):302-308.CrossRefPubMed
23.
Favaretto A, Poggiali D, Lazzarotto A, Rolma G, Causin F, Gallo P. The parallel analysis of phase sensitive inversion recovery (PSIR) and double inversion recovery (DIR) images significantly improves the detection of cortical lesions in multiple sclerosis (MS) since clinical onset. PLOS ONE 2015;10(5):e0127805.PubMedCentralCrossRefPubMed
24.
Futatsuya K, Kakeda S, Yoneda T, et al. Juxtacortical lesions in multiple sclerosis: assessment of gray matter involvement using phase difference-enhanced imaging (PADRE). Magn Reson Med Sci 2016;15(4):349-354.PubMedCentralCrossRefPubMed
25.
Nelson F, Poonawalla A, Hou P, Wolinsky JS, Narayana PA. 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 2008;14(9):1214-1219.CrossRefPubMed
26.
Harrison DM, Roy S, Oh J, et al. Association of cortical lesion burden on 7-T magnetic resonance imaging with cognition and disability in multiple sclerosis. JAMA Neurol 2015;72(9):1004-1012.PubMedCentralCrossRefPubMed
27.
Horakova D, Dwyer MG, Havrdova E, et al. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci 2009;282(1-2):112-119.CrossRefPubMed
28.
Moccia M, Quarantelli M, Lanzillo R, et al. Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression. Eur J Neurol 2017;24(1):195-204.CrossRefPubMed
29.
Zivadinov R, Havrdova E, Bergsland N, et al. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268(3):831-841.CrossRefPubMed
30.
Eshaghi A, Wottschel V, Cortese R, et al. Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. Neurology 2016;87(23):2463-2470.PubMedCentralCrossRefPubMed
31.
Bergsland N, Zivadinov R, Dwyer MG, Weinstock-Guttman B, Benedict RH. Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Mult Scler 2016;22(10):1327-1336.CrossRefPubMed
32.
Mahajan K, Nakamura, K, Vignos, M, et al. Thalamic MRI and histopathologic correlations in advanced multiple sclerosis. Neurology 2017;88(Suppl.S2.004).
33.
Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. NeuroImage 2005;26(1):132-140.CrossRefPubMed
34.
Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. NeuroImage 2002;17(3):1429-1436.CrossRefPubMed
35.
O'Donnell LJ, Westin CF. An introduction to diffusion tensor image analysis. Neurosurg Clin North Am 2011;22(2):185-196.CrossRef
36.
37.
Patel SA, Hum BA, Gonzalez CF, Schwartzman RJ, Faro SH, Mohamed FB. Application of voxelwise analysis in the detection of regions of reduced fractional anisotropy in multiple sclerosis patients. J Magn Reson Imaging 2007;26(3):552-556.CrossRefPubMed
38.
Poonawalla AH, Hasan KM, Gupta RK, et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findings. Radiology 2008;246(3):880-886.CrossRefPubMed
39.
Rocca MA, Preziosa P, Mesaros S, et al. Clinically isolated syndrome suggestive of multiple sclerosis: dynamic patterns of gray and white matter changes-a 2-year MR imaging study. Radiology 2016;278(3):841-853.CrossRefPubMed
40.
Rovaris M, Bozzali M, Iannucci G, et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch Neurol 2002;59(9):1406-1412.CrossRefPubMed
41.
Oreja-Guevara C, Rovaris M, Iannucci G, et al. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol 2005;62(4):578-584.CrossRefPubMed
42.
Chen J, Zhou C, Zhu L, et al. Magnetic resonance diffusion tensor imaging for occult lesion detection in multiple sclerosis. Exp Ther Med 2017;13(1):91-96.CrossRefPubMed
43.
Tovar-Moll F, Evangelou IE, Chiu AW, et al. Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T. AJNR Am J Neuroradiol 2009;30(7):1380-1386.CrossRefPubMed
44.
Deppe M, Kramer J, Tenberge JG, et al. Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis. Hum Brain Mapp 2016;37(5):1866-1879.CrossRefPubMed
45.
Rocca MA, Cercignani M, Iannucci G, Comi G, Filippi M. Weekly diffusion-weighted imaging of normal-appearing white matter in MS. Neurology 2000;55(6):882-884.CrossRefPubMed
46.
47.
Chiang GC, Pinto S, Comunale JP, Gauthier SA. Gadolinium-enhancing lesions lead to decreases in white matter tract fractional anisotropy in multiple sclerosis. J Neuroimaging 2016;26(3):289-295.CrossRefPubMed
48.
49.
Naismith RT, Xu J, Tutlam NT, et al. Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology 2010;74(21):1694-1701.PubMedCentralCrossRefPubMed
50.
Ontaneda D, Sakaie K, Lin J, et al. Measuring brain tissue integrity during 4 years using diffusion tensor imaging. AJNR Am J Neuroradiol 2017;38(1):31-38.CrossRefPubMed
51.
Louapre C, Govindarajan ST, Gianni C, et al. Is the relationship between cortical and white matter pathologic changes in multiple sclerosis spatially specific? A multimodal 7-T and 3-T MR imaging study with surface and tract-based analysis. Radiology 2016;278(2):524-535.CrossRefPubMed
52.
Keser Z, Hasan KM, Mwangi B, et al. Limbic pathway correlates of cognitive impairment in multiple sclerosis. J Neuroimaging 2017;27(1):37-42.CrossRefPubMed
53.
Yu HJ, Christodoulou C, Bhise V, et al. Multiple white matter tract abnormalities underlie cognitive impairment in RRMS. NeuroImage 2012;59(4):3713-3722.CrossRefPubMed
54.
Planche V, Ruet A, Coupe P, et al. Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2016 Oct 15.
55.
Hubbard EA, Wetter NC, Sutton BP, Pilutti LA, Motl RW. Diffusion tensor imaging of the corticospinal tract and walking performance in multiple sclerosis. J Neurol Sci 2016;363:225-231.CrossRefPubMed
56.
Prosperini L, Fanelli F, Petsas N, et al. Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board. Radiology 2014;273(2):529-538.CrossRefPubMed
57.
Brambilla L, Rossi Sebastiano D, Aquino D, et al. Early effect of dalfampridine in patients with MS: a multi-instrumental approach to better investigate responsiveness. J Neurol Sci 2016;368:402-407.CrossRefPubMed
58.
Senda J, Watanabe H, Endo K, et al. Active brain changes after initiating fingolimod therapy in multiple sclerosis patients using individual voxel-based analyses for diffusion tensor imaging. Nagoya J Med Sci 2016;78(4):455-463.PubMedCentralPubMed
59.
Wiebenga OT, Schoonheim MM, Hulst HE, et al. White matter diffusion changes during the first year of natalizumab treatment in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2016;37(6):1030-1037.CrossRefPubMed
60.
Ratzer R, Iversen P, Bornsen L, et al. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Mult Scler.2016;22(7):926-934.CrossRefPubMed
61.
Fox RJ, Coffey CS, Cudkowicz ME, et al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials 2016;50:166-177.PubMedCentralCrossRefPubMed
62.
Lin TH, Chiang CW, Perez-Torres CJ, et al. Diffusion MRI quantifies early axonal loss in the presence of nerve swelling. J Neuroinflammation 2017;14(1):78.PubMedCentralCrossRefPubMed
63.
Schneider T, Brownlee W, Zhang H, Ciccarelli O, Miller DH, Wheeler-Kingshott CG. Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study. Funct Neurol 2017;32(2):97-101.PubMedCentralCrossRefPubMed
64.
Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 1990;87(24):9868-9872.PubMedCentralCrossRefPubMed
65.
Faivre A, Rico A, Zaaraoui W, et al. Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. Mult Scler 2012;18(9):1251-1258.CrossRefPubMed
66.
Roosendaal SD, Schoonheim MM, Hulst HE, et al. Resting state networks change in clinically isolated syndrome. Brain 2010;133(Pt 6):1612-1621.CrossRefPubMed
67.
Liu Y, Duan Y, Liang P, et al. Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI. Acta Radiol 2012;53(9):1073-1078.CrossRefPubMed
68.
Giorgio A, Stromillo ML, De Leucio A, et al. Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures. J Neurosci 2015;35(2):550-558.CrossRefPubMed
69.
Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005;4(10):618-626.CrossRefPubMed
70.
Faivre A, Robinet E, Guye M, et al. Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: a longitudinal resting-state fMRI study. Mult Scler 2016;22(13):1695-1708.CrossRefPubMed
71.
Liu Y, Liang P, Duan Y, et al. Altered thalamic functional connectivity in multiple sclerosis. Eur J Radiol 2015;84(4):703-708.CrossRefPubMed
72.
Filippi M, Rocca MA, Mezzapesa DM, et al. Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Hum Brain Mapp 2004;21(2):108-117.CrossRefPubMed
73.
Giorgio A, Portaccio E, Stromillo ML, et al. Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Mult Scler 2010;16(11):1326-1334.CrossRefPubMed
74.
Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 2002;58(6):866-872.CrossRefPubMed
75.
Agosta F, Valsasina P, Absinta M, Sala S, Caputo D, Filippi M. Primary progressive multiple sclerosis: tactile-associated functional MR activity in the cervical spinal cord. Radiology 2009;253(1):209-215.CrossRefPubMed
76.
Audoin B, Reuter F, Duong MV, et al. Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. Mult Scler 2008;14(6):786-792.CrossRefPubMed
77.
Sbardella E, Upadhyay N, Tona F, et al. Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features. Mult Scler 2017;23(4):546-555.CrossRefPubMed
78.
Koini M, Filippi M, Rocca MA, et al. Correlates of executive functions in multiple sclerosis based on structural and functional MR imaging: insights from a multicenter study. Radiology 2016;280(3):869-879.CrossRefPubMed
79.
Nelson F, Akhtar MA, Zuniga E, et al. Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis. Mult Scler 2017;23:836-847.CrossRefPubMed
80.
Vacchi L, Rocca MA, Meani A, et al. Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: a clinical-imaging evaluation. Mult Scler 2017;23(4):577-587.CrossRefPubMed
81.
Schoonheim MM, Geurts JJ, Landi D, et al. Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data. Hum Brain Mapp 2013;34(1):52-61.CrossRefPubMed
82.
Specogna I, Casagrande F, Lorusso A, et al. Functional MRI during the execution of a motor task in patients with multiple sclerosis and fatigue. Radiol Med 2012;117(8):1398-1407.CrossRefPubMed
83.
Pravata E, Zecca C, Sestieri C, et al. Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue. Mult Scler 2016;22(13):1665-1675.CrossRefPubMed
84.
DeLuca J, Genova HM, Hillary FG, Wylie G. Neural correlates of cognitive fatigue in multiple sclerosis using functional MRI. J Neurol Sci 2008;270(1-2):28-39.CrossRefPubMed
85.
Bosnell R, Wegner C, Kincses ZT, et al. Reproducibility of fMRI in the clinical setting: implications for trial designs. NeuroImage 2008;42(2):603-610.CrossRefPubMed
86.
Hulst HE, Goldschmidt T, Nitsche MA, et al. rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2017;88:386-394.CrossRefPubMed
87.
De Giglio L, Tona F, De Luca F, et al. Multiple sclerosis: changes in thalamic resting-state functional connectivity induced by a home-based cognitive rehabilitation program. Radiology 2016;280(1):202-211.CrossRefPubMed
88.
Huiskamp M, Dobryakova E, Wylie GD, DeLuca J, Chiaravalloti ND. A pilot study of changes in functional brain activity during a working memory task after mSMT treatment: the MEMREHAB trial. Mult Scler Relat Disord 2016;7:76-82.PubMedCentralCrossRefPubMed
89.
Pinter D, Beckmann C, Koini M, et al. Reproducibility of resting state connectivity in patients with stable multiple sclerosis. PLOS ONE 2016;11(3):e0152158.PubMedCentralCrossRefPubMed
90.
Jovicich J, Minati L, Marizzoni M, et al. Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: a multicentric resting-state fMRI study. NeuroImage 2016;124(Pt A):442-454.CrossRefPubMed
91.
Costafreda SG, Brammer MJ, Vencio RZ, et al. Multisite fMRI reproducibility of a motor task using identical MR systems. J Magn Reson Imaging 2007;26(4):1122-1126.CrossRefPubMed
92.
Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 1989;10(1):135-144.CrossRefPubMed
93.
Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56(3):407-415.CrossRefPubMed
94.
Chen JT, Kuhlmann T, Jansen GH, et al. Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. NeuroImage 2007;36(4):1152-1158.CrossRefPubMed
95.
Pike GB, De Stefano N, Narayanan S, et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. Radiology 2000;215(3):824-830.CrossRefPubMed
96.
Fernando KT, Tozer DJ, Miszkiel KA, et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005;128(Pt 12):2911-2925.CrossRefPubMed
97.
Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000;21(6):1034-1038.PubMed
98.
Brown JW, Pardini M, Brownlee WJ, et al. An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis. Brain 2017;140(Pt 2):387-398.CrossRefPubMed
99.
Laule C, Vavasour IM, Whittall KP, et al. Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 2003;250(8):924-931.CrossRefPubMed
100.
Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006;129(Pt 10):2620-2627.CrossRefPubMed
101.
Abdel-Fahim R, Mistry N, Mougin O, et al. Improved detection of focal cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis. Mult Scler Relat Disord 2014;3(2):258-265.CrossRefPubMed
102.
Faiss JH, Dahne D, Baum K, et al. Reduced magnetisation transfer ratio in cognitively impaired patients at the very early stage of multiple sclerosis: a prospective, multicenter, cross-sectional study. BMJ Open 2014;4(4):e004409.PubMedCentralCrossRefPubMed
103.
Khalil M, Enzinger C, Langkammer C, et al. Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 2011;17(2):173-180.CrossRefPubMed
104.
van den Elskamp IJ, Knol DL, Vrenken H, et al. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler 2010;16(6):660-669.CrossRefPubMed
105.
Tao Y, Zhang X, Zivadinov R, et al. Immunologic and MRI markers of the therapeutic effect of IFN-beta-1a in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2015;2(6):e176.PubMedCentralCrossRefPubMed
106.
Inglese M, van Waesberghe JH, Rovaris M, et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003;60(5):853-860.CrossRefPubMed
107.
Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Front Biosci (Elite Ed.) 2012;4:1496-1504.CrossRef
108.
Arnold DL, Gold R, Kappos L, et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol 2014;261(12):2429-2437.PubMedCentralCrossRefPubMed
109.
Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 2015;84(11):1145-1152.PubMedCentralCrossRefPubMed
110.
Romme Christensen J, Ratzer R, Bornsen L, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014;82(17):1499-1507.CrossRefPubMed
111.
Zivadinov R, Dwyer MG, Hussein S, et al. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNbeta-1a in multiple sclerosis. Mult Scler 2012;18(8):1125-1134.CrossRefPubMed
112.
Button T, Altmann D, Tozer D, et al. Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler 2013;19(2):241-244.CrossRefPubMed
113.
Schwartzbach CJ, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. J Neurol 2017;264(2):304-315.CrossRefPubMed
114.
Al-Iedani O, Lechner-Scott J, Ribbons K, Ramadan S. Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. J Biomed Sci 2017;24(1):17.PubMedCentralCrossRefPubMed
115.
Jain S, Sima DM, Sanaei Nezhad F, et al. Patch-based super-resolution of MR spectroscopic images: application to multiple sclerosis. Front Neurosci 2017;11:13.PubMedCentralCrossRefPubMed
116.
Mathiesen HK, Tscherning T, Sorensen PS, et al. Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. Magn Reson Med 2005;53(4):750-759.CrossRefPubMed
117.
Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20(9):1619-1627.PubMed
118.
Orije J, Kara F, Guglielmetti C, et al. Longitudinal monitoring of metabolic alterations in cuprizone mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy. NeuroImage 2015;114:128-135.CrossRefPubMed
119.
Bellmann-Strobl J, Stiepani H, Wuerfel J, et al. MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol 2009;19(8):2066-2074.CrossRefPubMed
120.
De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58(1):65-70.CrossRefPubMed
121.
Wu X, Hanson LG, Skimminge A, et al. Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. Neurol Res 2014;36(8):701-708.CrossRefPubMed
122.
Rigotti DJ, Gonen O, Grossman RI, et al. Global N-acetylaspartate declines even in benign multiple sclerosis. AJNR Am J Neuroradiol 2011;32(1):204-209.PubMed
123.
Narayanan S, Francis SJ, Sled JG, et al. Axonal injury in the cerebral normal-appearing white matter of patients with multiple sclerosis is related to concurrent demyelination in lesions but not to concurrent demyelination in normal-appearing white matter. NeuroImage 2006;29(2):637-642.CrossRefPubMed
124.
Vafaeyan H, Ebrahimzadeh SA, Rahimian N, et al. Quantification of diagnostic biomarkers to detect multiple sclerosis lesions employing (1)H-MRSI at 3T. Australas Phys Eng Sci Med 2015;38(4):611-618.CrossRefPubMed
125.
Moussallieh FM, Elbayed K, Chanson JB, et al. Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. Mult Scler 2014;20(5):558-565.CrossRefPubMed
126.
Pardini M, Botzkowski D, Muller S, et al. The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography. Eur J Neurol 2016;23(12):1769-1774.CrossRefPubMed
127.
Chang L, Munsaka SM, Kraft-Terry S, Ernst T. Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. J Neuroimmune Pharmacol 2013;8(3):576-593.PubMedCentralCrossRefPubMed
128.
Rovira A, Alonso J. 1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. Neuroimaging Clin North Am 2013;23(3):459-474.CrossRef
129.
De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38(6):901-909.CrossRefPubMed
130.
Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121 (Pt 1):103-113.CrossRefPubMed
131.
Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999;122:513-521.CrossRefPubMed
132.
Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43(1):56-71.CrossRefPubMed
133.
Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128(Pt 5):1016-1025.CrossRefPubMed
134.
Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging 2010;28(2):163-170.CrossRefPubMed
135.
Inglese M, Li BS, Rusinek H, Babb JS, Grossman RI, Gonen O. Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 2003;50(1):190-195.CrossRefPubMed
136.
Tartaglia MC, Narayanan S, De Stefano N, et al. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J Neurol 2002;249(10):1382-1390.CrossRefPubMed
137.
Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11(10):597-606.CrossRefPubMed
138.
De Stefano N, Filippi M, Miller D, et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007;69(20):1942-1952.CrossRefPubMed
139.
Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248(11):979-986.CrossRefPubMed
140.
Parry A, Corkill R, Blamire AM, et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003;250(2):171-178.CrossRefPubMed
141.
Sarchielli P, Presciutti O, Tarducci R, et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 1998;64(2):204-212.PubMedCentralCrossRefPubMed
142.
Yetkin MF, Mirza M, Donmez H. Monitoring interferon beta treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis. Medicine 2016;95(36):e4782.PubMedCentralCrossRefPubMed
143.
Khan O, Seraji-Bozorgzad N, Bao F, et al. The relationship between brain MR spectroscopy and disability in multiple sclerosis: 20-year data from the U.S. Glatiramer Acetate Extension Study. J Neuroimaging 2017;27(1):97-106.CrossRefPubMed
144.
Sajja BR, Narayana PA, Wolinsky JS, Ahn CW. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 2008;14(1):73-80.CrossRefPubMed
145.
Mellergard J, Tisell A, Dahlqvist Leinhard O, et al. Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis. PLOS ONE 2012;7(9):e44739.PubMedCentralCrossRefPubMed
146.
Wiebenga OT, Klauser AM, Schoonheim MM, et al. Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2015;36(6):1116-1123.CrossRefPubMed
147.
Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4(2):159-169.CrossRefPubMed
148.
Sijens PE, Mostert JP, Irwan R, Potze JH, Oudkerk M, De Keyser J. Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res 2008;164(3):274-282.CrossRefPubMed
149.
Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8(3):280-291.CrossRefPubMed
150.
Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler 2014;20(14):1806-1813.CrossRefPubMed
151.
152.
Eisele P, Konstandin S, Griebe M, et al. Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI. Mult Scler 2016;22(8):1040-1047.CrossRefPubMed
153.
Inglese M, Madelin G, Oesingmann N, et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 2010;133(Pt 3):847-857.PubMedCentralCrossRefPubMed
154.
Zaaraoui W, Konstandin S, Audoin B, et al. Distribution of brain sodium accumulation correlates with disability in multiple sclerosis: a cross-sectional 23Na MR imaging study. Radiology 2012;264(3):859-867.CrossRefPubMed
155.
Maarouf A, Audoin B, Konstandin S, et al. Topography of brain sodium accumulation in progressive multiple sclerosis. MAGMA 2014;27(1):53-62.CrossRefPubMed
156.
Paling D, Solanky BS, Riemer F, et al. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain 2013;136(Pt 7):2305-2317.CrossRefPubMed
157.
Biller A, Pflugmann I, Badde S, et al. Sodium MRI in multiple sclerosis is compatible with intracellular sodium accumulation and inflammation-induced hyper-cellularity of acute brain lesions. Sci Rep 2016;6:31269.PubMedCentralCrossRefPubMed
158.
Petracca M, Vancea RO, Fleysher L, Jonkman LE, Oesingmann N, Inglese M. Brain intra- and extracellular sodium concentration in multiple sclerosis: a 7 T MRI study. Brain 2016;139(Pt 3):795-806.CrossRefPubMed
159.
Raftopoulos R, Hickman SJ, Toosy A, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016;15(3):259-269.CrossRefPubMed
160.
Yang C, Hao Z, Zhang L, Zeng L, Wen J. Sodium channel blockers for neuroprotection in multiple sclerosis. Cochrane Database Syst Rev 2015(10):CD010422.
161.
Debruyne JC, Versijpt J, Van Laere KJ, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003;10(3):257-264.CrossRefPubMed
162.
Versijpt J, Debruyne JC, Van Laere KJ, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 2005;11(2):127-134.CrossRefPubMed
163.
Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012;79(6):523-530.PubMedCentralCrossRefPubMed
164.
Rissanen E, Tuisku J, Rokka J, et al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand (1)(1)C-PK11195. J Nucl Med 2014;55(6):939-944.CrossRefPubMed
165.
Giannetti P, Politis M, Su P, et al. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis 2014;65:203-210.CrossRefPubMed
166.
Giannetti P, Politis M, Su P, et al. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain 2015;138(Pt 1):110-119.CrossRefPubMed
167.
Ratchford JN, Endres CJ, Hammoud DA, et al. Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol 2012;259(6):1199-1205.CrossRefPubMed
168.
Takano A, Piehl F, Hillert J, et al. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res 2013;3(1):30.PubMedCentralCrossRefPubMed
169.
Oh U, Fujita M, Ikonomidou VN, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 2011;6(3):354-361.CrossRefPubMed
170.
Park E, Gallezot JD, Delgadillo A, et al. (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 2015;42(7):1081-1092.CrossRefPubMed
171.
172.
Vas A, Shchukin Y, Karrenbauer VD, et al. Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients. J Neurol Sci 2008;264(1-2):9-17.CrossRefPubMed
173.
Rissanen E, Virta JR, Paavilainen T, et al. Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study. J Cerebral Blood Flow Metab 2013;33(9):1394-1401.CrossRef
174.
175.
Stankoff B, Freeman L, Aigrot MS, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol 2011;69(4):673-680.CrossRefPubMed
176.
Bodini B, Veronese M, Garcia-Lorenzo D, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol 2016 Feb 18.
177.
Matias-Guiu JA, Cabrera-Martin MN, Matias-Guiu J, et al. Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study. BMC Neurol 2015;15:243.PubMedCentralCrossRefPubMed
178.
Kindred JH, Koo PJ, Rudroff T. Glucose uptake of the spinal cord in patients with multiple sclerosis detected by (1)(8)F-fluorodeoxyglucose PET/CT after walking. Spinal Cord 2014;52(Suppl. 3):S11-S13.CrossRefPubMed
179.
Maffione AM, Rampin L, Grassetto G, L'Erario R, Colletti PM, Rubello D. 18F-FDG PET/CT in tumefactive multiple sclerosis. Clin Nucl Med 2014;39(8):750-751.CrossRefPubMed
180.
Bolcaen J, Acou M, Mertens K, et al. Structural and metabolic features of two different variants of multiple sclerosis: a PET/MRI study. J Neuroimaging 2013;23(3):431-436.CrossRefPubMed
181.
Derache N, Marie RM, Constans JM, Defer GL. Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. J Neurol Sci 2006;245(1-2):103-109.CrossRefPubMed
182.
Blinkenberg M, Jensen CV, Holm S, Paulson OB, Sorensen PS. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology 1999;53(1):149-153.CrossRefPubMed
183.
Blinkenberg M, Rune K, Jensen CV, et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000;54(3):558-564.CrossRefPubMed
184.
Paulesu E, Perani D, Fazio F, et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. NeuroImage 1996;4(2):87-96.CrossRefPubMed
185.
Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48(6):1566-1571.CrossRefPubMed
186.
Freeman L, Garcia-Lorenzo D, Bottin L, et al. The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study. Ann Neurol 2015;78(4):554-567.CrossRefPubMed
187.
188.
de Paula Faria D, de Vries EF, Sijbesma JW, Buchpiguel CA, Dierckx RA, Copray SC. PET imaging of glucose metabolism, neuroinflammation and demyelination in the lysolecithin rat model for multiple sclerosis. Mult Scler 2014;20(11):1443-1452.CrossRef
189.
190.
de Paula Faria D, de Vries EF, Sijbesma JW, Dierckx RA, Buchpiguel CA, Copray S. PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: a comparison between [11C]CIC and [11C]MeDAS. NeuroImage 2014;87:395-402.CrossRef
191.
Liu GJ, Middleton RJ, Hatty CR, et al. The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol 2014;24(6):631-653.CrossRefPubMed
192.
Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997;27(4):322-335.CrossRefPubMed
193.
194.
Vowinckel E, Reutens D, Becher B, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997;50(2):345-353.CrossRefPubMed
195.
Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321-2337.CrossRefPubMed
196.
Datta G, Violante IR, Scott G, et al. Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Mult Scler 2016 Nov 1.
197.
Okada M, Nakao R, Momosaki S, et al. Improvement of brain uptake for in vivo PET imaging of astrocytic oxidative metabolism using benzyl [1-(11)C]acetate. Appl Radiat Isot 2013;78:102-107.CrossRefPubMed
198.
Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med 2007;48(3):420-428.PubMed
199.
Martin A, Vazquez-Villoldo N, Gomez-Vallejo V, et al. In vivo imaging of system xc- as a novel approach to monitor multiple sclerosis. Eur J Nucl Med Mol Imaging 2016;43(6):1124-1138.CrossRefPubMed
200.
Buck D, Forschler A, Lapa C, et al. 18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. J Nucl Med 2012;53(8):1269-1276.CrossRefPubMed
201.
Derache N, Grassiot B, Mezenge F, et al. Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-remitting-multiple sclerosis patients at the earlier stage of the disease: a PET/MR study. Mult Scler Relat Disord 2013;2(4):362-369.CrossRefPubMed
202.
203.
204.
Moore GR, Leung E, MacKay AL, et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology 2000;55(10):1506-1510.CrossRefPubMed
205.
MacKay A, Whittall K, Adler J, Li D, Paty D, Graeb D. In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994;31(6):673-677.CrossRefPubMed
206.
Laule C, Leung E, Lis DK, et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler 2006;12(6):747-753.CrossRefPubMed
207.
Moore GR, Laule C, Mackay A, et al. Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. J Neurol 2008;255(11):1802-1811.CrossRefPubMed
208.
209.
Nguyen TD, Deh K, Monohan E, et al. Feasibility and reproducibility of whole brain myelin water mapping in 4 minutes using fast acquisition with spiral trajectory and adiabatic T2prep (FAST-T2) at 3T. Magn Reson Med 2016;76(2):456-465.CrossRefPubMed
210.
Kolind S, Matthews L, Johansen-Berg H, et al. Myelin water imaging reflects clinical variability in multiple sclerosis. NeuroImage 2012;60(1):263-270.CrossRefPubMed
211.
Oh SH, Bilello M, Schindler M, Markowitz CE, Detre JA, Lee J. Direct visualization of short transverse relaxation time component (ViSTa). NeuroImage 2013;83:485-492.CrossRefPubMed
212.
Laule C, Vavasour IM, Moore GR, et al. Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study. J Neurol 2004;251(3):284-293.CrossRefPubMed
213.
214.
215.
Stikov N, Campbell JS, Stroh T, et al. In vivo histology of the myelin g-ratio with magnetic resonance imaging. NeuroImage 2015;118:397-405.CrossRefPubMed
216.
Stikov N, Campbell JS, Stroh T, et al. Quantitative analysis of the myelin g-ratio from electron microscopy images of the macaque corpus callosum. Data Brief 2015;4:368-373.PubMedCentralCrossRefPubMed
217.
Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15(3):292-303.PubMedCentralCrossRefPubMed
218.
Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76(8):686-692.PubMedCentralCrossRefPubMed
219.
Patrucco L, Rojas JI, Cristiano E. Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes. J Neurol 2012;259(7):1317-1320.CrossRefPubMed
220.
Wheeler-Kingshott CA, Stroman PW, Schwab JM, et al. The current state-of-the-art of spinal cord imaging: applications. NeuroImage 2014;84:1082-1093.CrossRefPubMed
221.
Riederer I, Karampinos DC, Settles M, et al. Double inversion recovery sequence of the cervical spinal cord in multiple sclerosis and related inflammatory diseases. AJNR Am J Neuroradiol 2015;36(1):219-225.CrossRefPubMed
222.
Nair G, Absinta M, Reich DS. Optimized T1-MPRAGE sequence for better visualization of spinal cord multiple sclerosis lesions at 3T. AJNR Am J Neuroradiol 2013;34(11):2215-2222.PubMedCentralCrossRefPubMed
223.
Chong AL, Chandra RV, Chuah KC, Roberts EL, Stuckey SL. Proton density MRI increases detection of cervical spinal cord multiple sclerosis lesions compared with T2-weighted fast spin-echo. AJNR Am J Neuroradiol 2016;37(1):180-184.CrossRefPubMed
224.
Weier K, Mazraeh J, Naegelin Y, et al. Biplanar MRI for the assessment of the spinal cord in multiple sclerosis. Mult Scler 2012;18(11):1560-1569.CrossRefPubMed
225.
Philpott C, Brotchie P. Comparison of MRI sequences for evaluation of multiple sclerosis of the cervical spinal cord at 3 T. Eur J Radiol 2011;80(3):780-785.CrossRefPubMed
226.
Breckwoldt MO, Gradl J, Hahnel S, et al. Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. J Neurol 2017;264(2):341-349.CrossRefPubMed
227.
Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62(2):226-233.CrossRefPubMed
228.
Brex PA, Leary SM, O'Riordan JI, et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70(4):544-547.PubMedCentralCrossRefPubMed
229.
Brownlee WJ, Altmann DR, Alves Da Mota P, et al. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler 2017;23(5):665-674.CrossRefPubMed
230.
Nijeholt GJ, Bergers E, Kamphorst W, et al. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype. Brain 2001;124(Pt 1):154-166.CrossRefPubMed
231.
Kearney H, Altmann DR, Samson RS, et al. Cervical cord lesion load is associated with disability independently from atrophy in MS. Neurology 2015;84(4):367-373.CrossRefPubMed
232.
Lukas C, Knol DL, Sombekke MH, et al. Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015;86(4):410-418.CrossRefPubMed
233.
Liptak Z, Berger AM, Sampat MP, et al. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol 2008;29(8):1465-1470.CrossRefPubMed
234.
Bernitsas E, Bao F, Seraji-Bozorgzad N, et al. Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes. Mult Scler Relat Disord 2015;4(1):47-51.CrossRefPubMed
235.
Gilmore CP, Geurts JJ, Evangelou N, et al. Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. Mult Scler 2009;15(2):180-188.CrossRefPubMed
236.
Schlaeger R, Papinutto N, Panara V, et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol 2014;76(4):568-580.PubMedCentralCrossRefPubMed
237.
Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol 2015;72(8):897-904.CrossRefPubMed
238.
Kearney H, Miszkiel KA, Yiannakas MC, Altmann DR, Ciccarelli O, Miller DH. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis. Mult Scler 2016;22(7):910-920.CrossRefPubMed
239.
Hua LH, Donlon SL, Sobhanian MJ, Portner SM, Okuda DT. Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement in multiple sclerosis. Spinal Cord 2015;53(7):520-525.CrossRefPubMed
240.
Qiu W, Raven S, James I, et al. Spinal cord involvement in multiple sclerosis: a correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci 2011;300(1-2):114-119.CrossRefPubMed
241.
Akkad DA, Bellenberg B, Esser S, et al. Multiple sclerosis risk loci correlate with cervical cord atrophy and may explain the course of disability. Neurogenetics 2015;16(3):161-168.CrossRefPubMed
242.
Valsasina P, Rocca MA, Horsfield MA, Copetti M, Filippi M. A longitudinal MRI study of cervical cord atrophy in multiple sclerosis. J Neurol 2015;262(7):1622-1628.CrossRefPubMed
243.
Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003;74(8):1090-1094.PubMedCentralCrossRefPubMed
244.
Shipova EG, Spirin NN, Kasatkin DS, Shumakov EI, Stepanov IO. State of the cervical section of the spinal cord in patients with remitting multiple sclerosis during immunomodulatory treatment. Neurosci Behav Physiol 2009;39(1):47-51.CrossRefPubMed
245.
Singhal T, Tauhid S, Hurwitz S, Neema M, Bakshi R. The effect of glatiramer acetate on spinal cord volume in relapsing-remitting multiple sclerosis. J Neuroimaging 2017;27(1):33-36.CrossRefPubMed
246.
Martin AR, Aleksanderek I, Cohen-Adad J, et al. Translating state-of-the-art spinal cord MRI techniques to clinical use: a systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI. NeuroImage Clin 2016;10:192-238.CrossRefPubMed
247.
Oh J, Zackowski K, Chen M, et al. Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. Mult Scler 2013;19(4):427-435.CrossRefPubMed
248.
Zollinger LV, Kim TH, Hill K, Jeong EK, Rose JW. Using diffusion tensor imaging and immunofluorescent assay to evaluate the pathology of multiple sclerosis. J Magn Reson Imaging 2011;33(3):557-564.PubMedCentralCrossRefPubMed
249.
Theaudin M, Saliou G, Ducot B, et al. Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study. Neuroradiol 2012;54(10):1171-1178.CrossRef
250.
Oh J, Sotirchos ES, Saidha S, et al. Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology 2015;84(7):720-728.PubMedCentralCrossRefPubMed
251.
Hesseltine SM, Law M, Babb J, et al. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord. AJNR Am J Neuroradiol 2006;27(6):1189-1193.PubMed
252.
Benedetti B, Rocca MA, Rovaris M, et al. A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2010;81(1):26-30.CrossRefPubMed
253.
Kearney H, Schneider T, Yiannakas MC, et al. Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015;86(6):608-614.CrossRefPubMed
254.
Minty EP, Bjarnason TA, Laule C, MacKay AL. Myelin water measurement in the spinal cord. Magn Reson Med 2009;61(4):883-892.CrossRefPubMed
255.
Laule C, Yung A, Pavolva V, et al. High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report. Mult Scler 2016;22(11):1485-1489.CrossRefPubMed
256.
Laule C, Vavasour IM, Zhao Y, et al. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis. Mult Scler 2010;16(6):670-677.CrossRefPubMed
257.
Henning A, Schar M, Kollias SS, Boesiger P, Dydak U. Quantitative magnetic resonance spectroscopy in the entire human cervical spinal cord and beyond at 3T. Magn Reson Med 2008;59(6):1250-1258.CrossRefPubMed
258.
Marliani AF, Clementi V, Albini Riccioli L, et al. Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 2010;31(1):180-184.CrossRefPubMed
259.
Ciccarelli O, Wheeler-Kingshott CA, McLean MA, et al. Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 2007;130(Pt 8):2220-2231.CrossRefPubMed
260.
Smith AK, Dortch RD, Dethrage LM, Smith SA. Rapid, high-resolution quantitative magnetization transfer MRI of the human spinal cord. NeuroImage 2014;95:106-116.PubMedCentralCrossRefPubMed
261.
Zackowski KM, Smith SA, Reich DS, et al. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009;132(Pt 5):1200-1209.PubMedCentralCrossRefPubMed
262.
Agosta F, Pagani E, Caputo D, Filippi M. Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis. Arch Neurol 2007;64(9):1302-1305.CrossRefPubMed
263.
Rovaris M, Judica E, Sastre-Garriga J, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 2008;14(4):455-464.CrossRefPubMed
264.
Kearney H, Yiannakas MC, Samson RS, Wheeler-Kingshott CA, Ciccarelli O, Miller DH. Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord. Brain 2014;137(Pt 9):2456-2468.CrossRefPubMed
265.
Rocca MA, Absinta M, Valsasina P, et al. Abnormal cervical cord function contributes to fatigue in multiple sclerosis. Mult Scler 2012;18(11):1552-1559.CrossRefPubMed
266.
Valsasina P, Agosta F, Absinta M, Sala S, Caputo D, Filippi M. Cervical cord functional MRI changes in relapse-onset MS patients. J Neurol Neurosurg Psychiatry 2010;81(4):405-408.CrossRefPubMed
267.
Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68(4):477-493.CrossRefPubMed
268.
Zivadinov R, Ramasamy DP, Vaneckova M, et al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: a retrospective, pilot, observational longitudinal study. Mult Scler 2016 Nov 1.
269.
Absinta M, Vuolo L, Rao A, et al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85(1):18-28.PubMedCentralCrossRefPubMed
270.
Absinta M, Cortese IC, Vuolo L, et al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology 2017;88:1439-1444.CrossRefPubMed
271.
Sastre-Garriga J. Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected? Mult Scler 2016;22(7):975-976.CrossRefPubMed
272.
Xia Z, Steele SU, Bakshi A, et al. Assessment of early evidence of multiple sclerosis in a prospective study of asymptomatic high-risk family members. JAMA Neurol 2017;74:293-300.PubMed
273.
Connor JR, Menzies SL. Cellular management of iron in the brain. J Neurol Sci 1995;134(Suppl.):33-44.
274.
Hametner S, Wimmer I, Haider L, Pfeifenbring S, Bruck W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74(6):848-861.PubMedCentralCrossRefPubMed
275.
Zhang X, Haaf M, Todorich B, et al. Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 2005;52(3):199-208.CrossRefPubMed
276.
277.
Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017;133(1):25-42.CrossRefPubMed
278.
Yao B, Ikonomidou VN, Cantor FK, Ohayon JM, Duyn J, Bagnato F. Heterogeneity of multiple sclerosis white matter lesions detected with T2*-weighted imaging at 7.0 Tesla. J Neuroimaging 2015;25(5):799-806.PubMedCentralCrossRefPubMed
279.
Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest 2016;126(7):2597-2609.PubMedCentralCrossRefPubMed
280.
Al-Radaideh AM, Wharton SJ, Lim SY, et al. Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in clinically isolated syndrome. Mult Scler 2013;19(7):896-903.CrossRefPubMed
281.
Habib CA, Liu M, Bawany N, et al. Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls. AJNR Am J Neuroradiol 2012;33(2):252-258.CrossRefPubMed
282.
Quinn MP, Gati JS, Klassen ML, Lee DH, Kremenchutzky M, Menon RS. Increased deep gray matter iron is present in clinically isolated syndromes. Mult Scler Relat Disord 2014;3(2):194-202.CrossRefPubMed
283.
Bergsland N, Tavazzi E, Lagana MM, et al. White matter tract injury is associated with deep gray matter iron deposition in multiple sclerosis. J Neuroimaging 2017;27(1):107-113.CrossRefPubMed
284.
Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 2006;12(4):437-444.CrossRefPubMed
285.
Modica CM, Zivadinov R, Dwyer MG, Bergsland N, Weeks AR, Benedict RH. Iron and volume in the deep gray matter: association with cognitive impairment in multiple sclerosis. AJNR Am J Neuroradiol 2015;36(1):57-62.CrossRefPubMed
286.
Paling D, Tozer D, Wheeler-Kingshott C, Kapoor R, Miller DH, Golay X. Reduced R2' in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content. J Neurol Neurosurg Psychiatry 2012;83(8):785-792.CrossRefPubMed
287.
Trattnig S, Springer E, Bogner W, et al. Key clinical benefits of neuroimaging at 7T. NeuroImage 2016 Nov 13 [Epub ahead of print].
288.
Tjoa CW, Benedict RH, Weinstock-Guttman B, Fabiano AJ, Bakshi R. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005;234(1-2):17-24.CrossRefPubMed
289.
Cronin MJ, Wharton S, Al-Radaideh A, et al. A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field. MAGMA 2016;29(3):543-557.PubMedCentralCrossRefPubMed
290.
Bagnato F, Hametner S, Yao B, et al. Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134(Pt 12):3602-3615.CrossRefPubMed
291.
Pitt D, Boster A, Pei W, et al. Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 2010;67(7):812-818.CrossRefPubMed
292.
Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64(6):707-713.CrossRefPubMed
293.
Absinta M, Sati P, Gaitan MI, et al. Seven-tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013;74(5):669-678.CrossRefPubMed
294.
Ge Y, Jensen JH, Lu H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28(9):1639-1644.CrossRefPubMed
295.
Kilsdonk ID, Wattjes MP, Lopez-Soriano A, et al. Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. Eur Radiol 2014;24(4):841-849.CrossRefPubMed
296.
Chen X, Zeng C, Luo T, et al. Iron deposition of the deep grey matter in patients with multiple sclerosis and neuromyelitis optica: a control quantitative study by 3D-enhanced susceptibility-weighted angiography (ESWAN). Eur J Radiol 2012;81(4):e633-e639.CrossRefPubMed
297.
Sheth VR, Fan S, He Q, et al. Inversion recovery ultrashort echo time magnetic resonance imaging: a method for simultaneous direct detection of myelin and high signal demonstration of iron deposition in the brain—a feasibility study. Magn Reson Imaging 2017;38:87-94.CrossRefPubMed
298.
Kirschbaum K, Sonner JK, Zeller MW, et al. In vivo nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. Proc Natl Acad Sci U S A 2016;113(46):13227-13232.PubMedCentralCrossRefPubMed
299.
Crimi A, Commowick O, Maarouf A, et al. Predictive value of imaging markers at multiple sclerosis disease onset based on gadolinium- and USPIO-enhanced MRI and machine learning. PLOS ONE 2014;9(4):e93024.PubMedCentralCrossRefPubMed
300.
Maarouf A, Ferre JC, Zaaraoui W, et al. Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome. Mult Scler 2016;22(8):1032-1039.CrossRefPubMed
301.
Wisnieff C, Ramanan S, Olesik J, Gauthier S, Wang Y, Pitt D. Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: interpreting positive susceptibility and the presence of iron. Magn Reson Med 2015;74(2):564-570.CrossRefPubMed
302.
Zhang Y, Gauthier SA, Gupta A, et al. Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM). J Magn Reson Imaging 2016;44(2):426-432.PubMedCentralCrossRefPubMed
303.
Chen W, Gauthier SA, Gupta A, et al. Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271(1):183-192..PubMedCentralCrossRefPubMed
304.
Fujiwara E, Kmech JA, Cobzas D, et al. Cognitive implications of deep gray matter iron in multiple sclerosis. AJNR Am J Neuroradiol 2017;38:942-948.CrossRefPubMed
305.
Schmalbrock P, Prakash RS, Schirda B, et al. Basal ganglia iron in patients with multiple sclerosis measured with 7T quantitative susceptibility mapping correlates with inhibitory control. AJNR Am J Neuroradiol 2016;37(3):439-446.CrossRefPubMed
306.
Chawla S, Kister I, Wuerfel J, et al. Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optica lesions at 7T MRI. AJNR Am J Neuroradiol 2016;37(7):1223-1230.PubMedCentralCrossRefPubMed
307.
Solomon AJ, Schindler MK, Howard DB, et al. "Central vessel sign" on 3T FLAIR* MRI for the differentiation of multiple sclerosis from migraine. Ann Clin Transl Neurol 2016;3(2):82-87.CrossRefPubMed
308.
Sati P, Oh J, Constable RT, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 2016;12(12):714-722.CrossRefPubMed
309.
310.
Nakamura K, Deshmane A, Guruprakash D, et al. A novel method for quantification of normal appearing brain tissue in multiple sclerosis: magnetic resonance fingerprinting (P4.158). Neurology 2016;86(16 Suppl.).
311.
Hamilton JI, Jiang Y, Chen Y, et al. MR fingerprinting for rapid quantification of myocardial T1, T2, and proton spin density. Magn Reson Med 2017;77(4):1446-1458.CrossRefPubMed
Metadata
Title
The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials
Authors
Kedar R. Mahajan
Daniel Ontaneda
Publication date
01-10-2017
Publisher
Springer US
Published in
Neurotherapeutics / Issue 4/2017
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-017-0561-8

Other articles of this Issue 4/2017

Neurotherapeutics 4/2017 Go to the issue

Review

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

Review

Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials

Original Article

Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model

Original Article

Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels

Review

Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis

Review

Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics